Investigations of Coagulation System and Fibrinolysis in Patients with Disseminated Adenocarcinomas and Non-Hodgkin’s Lymphomas

Publisher Website
Google Scholar
Abstract
Indicating activation of coagulation fibrinopeptide A (FPA) was elevated in 80.1% (.hivin.x = 10.5 ng/ml; p < 0.01) and thrombin-antithrombin III complexes in 58.3% (TAT; .hivin.x = 5.3 ng/ml; p < 0.05) in patients with adenocarcinomas (n = 57). In patients with non-Hodgkin''s lymphomas (n = 30), however, elevation was observed only in 66.6% (FPA) and in 42.8% (TAT). Incidence of thrombosis is high only in the first group. Local fibrinolysis explains elevated D-dimer in adrenocarcinomas (1,818 ng/ml; p < 0.01) and in non-Hodgkin''s lymphomas (576 ng/ml; p < 0.05). Significantly increased t-PA antigen was not committed by adequately increased t-PA activity in adenocarcinomas, because of high levels of the acute-phase protein, plasmingoen activator inhibitor (.hivin.x = 25.3; p < 0.01), indicating systemic hypofibrinolysis. Hemostatic disorder in patients with malignancy can be attributed to a combination of acute-phase reaction and an activation of coagulation.